GenFleet Therapeutics

<form id="91v9l"></form>

<address id="91v9l"></address><noframes id="91v9l">

<form id="91v9l"></form>

<form id="91v9l"><nobr id="91v9l"></nobr></form>

<noframes id="91v9l">

Innovent Biologics Pays GenFleet $22M Upfront for Rights to KRAS G12C Inhibitor in Greater China | Precision Oncology News

Shanghai-based GenFleet has been developing GFH925 as a treatment for non-small cell lung cancer and other solid tumors.

Sep 06, 2021
Innovent and GenFleet reach deal for KRAS inhibitor | Endpoints

Chinese pharma companies Innovent and GenFleet have entered into an exclusive licensing agreement for developing and commercializing GenFleet’s GFH925, the company’s lead KRAS G12C candidate in the China, Hong Kong, Macau and Taiwan markets.

Sep 02, 2021
China's GenFleet banks $58M for cancer, autoimmune pipeline | Fierce Biotech

GenFleet Therapeutics raised $58 million in series B funding to bankroll clinical trials of its pipeline, including a small molecule for liver cancer.

Mar 10, 2020
Chinese biotech bags $50M+ for I/O, autoimmune work, starting with ALK5 inhibitor l Endpoints

For the last decade or so, many of the more eye-catching Chinese biotech startups share two defining attributes

Mar 09, 2020
After Ally Bridge-backed series A, Shanghai's GenFleet looks to Clinic丨BioCentury

With eight preclinical candidates and an experienced management team, immunology company GenFleet Therapeutics Co. Ltd. (Shanghai, China) raised RMB120 million ($17.4 million) in an untranched series A round to bring its first therapy into clinic next year.

Dec 06, 2018

2

成人Av鲁丝片一区二区免费,亚洲欧洲成人,亚洲精品成人,久久久WWW成人免费毛片 (function(){ var bp = document.createElement('script'); var curProtocol = window.location.protocol.split(':')[0]; if (curProtocol === 'https') { bp.src = 'https://zz.bdstatic.com/linksubmit/push.js'; } else { bp.src = 'http://push.zhanzhang.baidu.com/push.js'; } var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(bp, s); })();